Cargando…
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
BACKGROUND: Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality and continue to impose a high disease burden on affected patients. Therefore, we sought to determine potential predictors for MC and exacerbation as well as to identify fac...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005160/ https://www.ncbi.nlm.nih.gov/pubmed/35413850 http://dx.doi.org/10.1186/s12974-022-02448-4 |
_version_ | 1784686397170384896 |
---|---|
author | Nelke, Christopher Stascheit, Frauke Eckert, Carmen Pawlitzki, Marc Schroeter, Christina B. Huntemann, Niklas Mergenthaler, Philipp Arat, Ercan Öztürk, Menekse Foell, Dirk Schreiber, Stefanie Vielhaber, Stefan Gassa, Asmae Stetefeld, Henning Schroeter, Michael Berger, Benjamin Totzeck, Andreas Hagenacker, Tim Meuth, Sven G. Meisel, Andreas Wiendl, Heinz Ruck, Tobias |
author_facet | Nelke, Christopher Stascheit, Frauke Eckert, Carmen Pawlitzki, Marc Schroeter, Christina B. Huntemann, Niklas Mergenthaler, Philipp Arat, Ercan Öztürk, Menekse Foell, Dirk Schreiber, Stefanie Vielhaber, Stefan Gassa, Asmae Stetefeld, Henning Schroeter, Michael Berger, Benjamin Totzeck, Andreas Hagenacker, Tim Meuth, Sven G. Meisel, Andreas Wiendl, Heinz Ruck, Tobias |
author_sort | Nelke, Christopher |
collection | PubMed |
description | BACKGROUND: Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality and continue to impose a high disease burden on affected patients. Therefore, we sought to determine potential predictors for MC and exacerbation as well as to identify factors affecting outcome. METHODS: We examined a retrospective, observational cohort study of patients diagnosed with MG between 2000 and 2021 with a mean follow-up of 62.6 months after diagnosis from eight tertiary hospitals in Germany. A multivariate Cox regression model with follow-up duration as the time variable was used to determine independent risk factors for MC and disease exacerbation. RESULTS: 815 patients diagnosed with MG according to national guidelines were included. Disease severity at diagnosis (quantitative MG score or Myasthenia Gravis Foundation of America class), the presence of thymoma and anti-muscle specific tyrosine kinase-antibodies were independent predictors of MC or disease exacerbation. Patients with minimal manifestation status 12 months after diagnosis had a lower risk of MC and disease exacerbation than those without. The timespan between diagnosis and the start of immunosuppressive therapy did not affect risk. Patients with a worse outcome of MC were older, had higher MGFA class before MC and at admission, and had lower vital capacity before and at admission. The number of comorbidities, requirement for intubation, prolonged mechanical ventilation, and MC triggered by infection were associated with worse outcome. No differences between outcomes were observed comparing treatments with IVIG (intravenous immunoglobulin) vs. plasma exchange vs. IVIG together with plasma exchange. CONCLUSIONS: MC and disease exacerbations inflict a substantial burden of disease on MG patients. Disease severity at diagnosis and antibody status predicted the occurrence of MC and disease exacerbation. Intensified monitoring with emphasis on the prevention of infectious complications could be of value to prevent uncontrolled disease in MG patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02448-4. |
format | Online Article Text |
id | pubmed-9005160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90051602022-04-13 Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients Nelke, Christopher Stascheit, Frauke Eckert, Carmen Pawlitzki, Marc Schroeter, Christina B. Huntemann, Niklas Mergenthaler, Philipp Arat, Ercan Öztürk, Menekse Foell, Dirk Schreiber, Stefanie Vielhaber, Stefan Gassa, Asmae Stetefeld, Henning Schroeter, Michael Berger, Benjamin Totzeck, Andreas Hagenacker, Tim Meuth, Sven G. Meisel, Andreas Wiendl, Heinz Ruck, Tobias J Neuroinflammation Research BACKGROUND: Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality and continue to impose a high disease burden on affected patients. Therefore, we sought to determine potential predictors for MC and exacerbation as well as to identify factors affecting outcome. METHODS: We examined a retrospective, observational cohort study of patients diagnosed with MG between 2000 and 2021 with a mean follow-up of 62.6 months after diagnosis from eight tertiary hospitals in Germany. A multivariate Cox regression model with follow-up duration as the time variable was used to determine independent risk factors for MC and disease exacerbation. RESULTS: 815 patients diagnosed with MG according to national guidelines were included. Disease severity at diagnosis (quantitative MG score or Myasthenia Gravis Foundation of America class), the presence of thymoma and anti-muscle specific tyrosine kinase-antibodies were independent predictors of MC or disease exacerbation. Patients with minimal manifestation status 12 months after diagnosis had a lower risk of MC and disease exacerbation than those without. The timespan between diagnosis and the start of immunosuppressive therapy did not affect risk. Patients with a worse outcome of MC were older, had higher MGFA class before MC and at admission, and had lower vital capacity before and at admission. The number of comorbidities, requirement for intubation, prolonged mechanical ventilation, and MC triggered by infection were associated with worse outcome. No differences between outcomes were observed comparing treatments with IVIG (intravenous immunoglobulin) vs. plasma exchange vs. IVIG together with plasma exchange. CONCLUSIONS: MC and disease exacerbations inflict a substantial burden of disease on MG patients. Disease severity at diagnosis and antibody status predicted the occurrence of MC and disease exacerbation. Intensified monitoring with emphasis on the prevention of infectious complications could be of value to prevent uncontrolled disease in MG patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02448-4. BioMed Central 2022-04-12 /pmc/articles/PMC9005160/ /pubmed/35413850 http://dx.doi.org/10.1186/s12974-022-02448-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Nelke, Christopher Stascheit, Frauke Eckert, Carmen Pawlitzki, Marc Schroeter, Christina B. Huntemann, Niklas Mergenthaler, Philipp Arat, Ercan Öztürk, Menekse Foell, Dirk Schreiber, Stefanie Vielhaber, Stefan Gassa, Asmae Stetefeld, Henning Schroeter, Michael Berger, Benjamin Totzeck, Andreas Hagenacker, Tim Meuth, Sven G. Meisel, Andreas Wiendl, Heinz Ruck, Tobias Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients |
title | Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients |
title_full | Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients |
title_fullStr | Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients |
title_full_unstemmed | Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients |
title_short | Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients |
title_sort | independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005160/ https://www.ncbi.nlm.nih.gov/pubmed/35413850 http://dx.doi.org/10.1186/s12974-022-02448-4 |
work_keys_str_mv | AT nelkechristopher independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT stascheitfrauke independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT eckertcarmen independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT pawlitzkimarc independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT schroeterchristinab independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT huntemannniklas independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT mergenthalerphilipp independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT aratercan independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT ozturkmenekse independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT foelldirk independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT schreiberstefanie independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT vielhaberstefan independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT gassaasmae independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT stetefeldhenning independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT schroetermichael independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT bergerbenjamin independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT totzeckandreas independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT hagenackertim independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT meuthsveng independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT meiselandreas independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT wiendlheinz independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients AT rucktobias independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients |